On Friday, AbbVie Inc (NYSE:ABBV)’s shares declined -0.17% to $70.04.
C2N Diagnostics and AbbVie (ABBV) declared the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the first treatment option accessible in all 28 member states of the European Union (EU) for the treatment of Waldenstrom’s macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one preceding therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Pharmacyclics LLC, an AbbVie company, received FDA approval for IMBRUVICA, which is also the first and only FDA-approved treatment for WM in the United States, in January 2015.1 The approval of IMBRUVICA to treat patients with WM triggers a $20 million milestone payment from Janssen.
IMBRUVICA is jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc. In Europe, Janssen-Cilag International NV (Janssen) holds the marketing authorization and its associates market IMBRUVICA in EMEA (Europe, Middle East, Africa), in addition to the rest of the world. IMBRUVICA is already approved in Europe to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukemia (CLL) who have received at least one preceding therapy or in first line use in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
MannKind Corporation(NASDAQ:MNKD)’s shares dropped -3.81% to $4.29.
MannKind Corporation (MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy.
Held in conjunction with the 75th annual American Diabetes Association Scientific Sessions in Boston, the reception was co-hosted by Kelly L. Close, leading diabetes advocate and founder of the diaTribe Foundation, along with Dr. Steven Edelman, nationally recognized endocrinologist and founder of Take Control of Your Diabetes (TCOYD). In addition to last night’s honors, Mr. Mann was also recently awarded the JDRF’s Lifetime Achievement Award, one of the leading awards in diabetes internationally.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
At the end of Friday’s trade, E I Du Pont De Nemours And Co(NYSE:DD)‘s shares surged 0.31% to $55.76.
DuPont declared it has accomplished the separation of its Performance Chemicals segment through the spin-off of The Chemours Company (Chemours). Chemours starts “regular way” trading recently on the New York Stock Exchange (NYSE) under the symbol “CC”. Recently DuPont common stockholders receive one share of common stock of Chemours for every five shares of DuPont common stock they held at 5:00 p.m. ET on June 23, 2015. DuPont common stockholders will receive cash in lieu of fractional shares of Chemours.
DuPont (DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can assist find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.
E.I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides. Its Electronics & Communications segment provides various materials and systems, counting photopolymers and electronic materials for photovoltaic products, consumer electronics, displays, and advanced printing.
Synaptics, Incorporated(NASDAQ:SYNA), ended its Friday’s trading session with 0.14% gain, and closed at $79.38.
Synaptics, Incorporated (SYNA) declared that Xiaomi, one of the world’s largest mobile manufacturers, has adopted the Synaptics® ClearPad® family of capacitive touchscreen solutions and its family of display driver integrated circuits (DDICs) for its latest smartphones, the Xiaomi Mi Note and Note Pro. By leveraging ClearPad for full in-cell display solutions and DDICs in discrete display implementations, Xiaomi is able to offer customers industry-leading touchscreen performance backed by brighter and sharper Full HD and Wide Quad HD (WQHD) displays.
These latest design wins demonstrate Synaptics’ continued momentum in China and leadership in the broader global mobile market. Xiaomi’s implementations of Synaptics’ solutions is further validation of the strong trend toward touch and display integration being adopted by global OEMs.
Synaptics Incorporated develops, markets, and sells custom-designed human interface solutions for electronic devices and products primarily in China, South Korea, Taiwan, the United States, Japan, and other countries. The company offers its human interface solutions for mobile product applications, counting smartphones, tablets, and touchscreen applications, in addition to mobile, handheld, wireless, and entertainment devices; and other personal computer (PC) product applications, such as peripherals comprising keyboards, mice, and monitors, in addition to remote control devices for desktops, PCs, and digital home applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
